Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN remedy product in US

The product, a novel dimeric G-CSF long-acting fusion protein with out pegylation, is presently underneath late-stage assessment by the US Meals and Drug Administration for chemotherapy-induced neutropenia (CIN).